

- yl]oxy}-3-{2-[(2-{3-[(1,3-dimethoxypropan-2-yl)oxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoate;
- (2*R*)-2-{[(5*S_a*)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-*d*]pyrimidin-4-yl]oxy}-3-[2-(2-[5-(hydroxymethyl)pyridin-3-yl]pyrimidin-4-yl)methoxy]phenyl}propanoic acid; and
 - (2*R*)-2-{[(5*S_a*)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-*d*]pyrimidin-4-yl]oxy}-3-(2-{[2'-(hydroxymethyl)-2,5'-bipyrimidin-4-yl]methoxy}phenyl)propanoic acid.
24. A pharmaceutical composition comprising the compound according to claim 1, or an addition salt thereof with a pharmaceutically acceptable acid or base, in combination with one or more pharmaceutically acceptable excipients.
25. Use of a pro-apoptotic agent in the manufacture of a medicament for treating a condition in a subject in need thereof, comprising administration of an effective amount of the compound according to claim 1, alone or in combination with one or more pharmaceutically acceptable excipients.
26. The use according to claim 25, wherein the condition is selected from cancer, autoimmune diseases, and immune system diseases.
27. The use according to claim 25, wherein the condition is selected from cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.
28. A combination of the compound according to claim 1 with an anti-cancer agent selected from genotoxic agents, mitotic poisons, anti-metabolites, proteasome inhibitors, kinase inhibitors and antibodies.
29. A pharmaceutical composition comprising the combination according to claim 28, in

combination with one or more pharmaceutically acceptable excipients.

- 30.** Use of the combination according to claim 28 in the manufacture of a medicament for treating cancer in a subject in need thereof comprising administration of the combination alone or in combination with one or more pharmaceutically acceptable excipients.
- 31.** Use of the compound according to claim 1 in the manufacture of a medicament for treating cancer requiring radiotherapy in a subject in need thereof comprising administration of the compound alone or in combination with one or more pharmaceutically acceptable excipients.